FDA Asked To Define Protocol Clearly For Individual BE Interim Study
Executive Summary
FDA should establish a clearly defined protocol prior to entering a two-year interim study to validate individual bioequivalence for regulatory policy, FDA's Pharmaceutical Science Advisory Committee agreed at its Sept. 23 meeting.